June 20, 2017
Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency
April 06, 2017
Innocrin Pharmaceuticals Appoints Fred Eshelman, PharmD as CEO and is Granted Fast Track Designation by FDA for Seviteronel Treatment of Women with Triple-negative Breast Cancer and Women or Men with Estrogen Receptor-positive Breast Cancer
December 13, 2016
Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium
October 5, 2016
Innocrin Pharmaceuticals, Inc. Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC)
May 12, 2016
Innocrin Pharmaceuticals Inc. Begins Phase 2 Breast Cancer Study and Expands 2 Phase 2 Prostate Cancer Studies
January 7, 2016
Innocrin Pharmaceuticals, Inc. Granted Fast Track Designation by FDA
July 1, 2015
Charles Osborne joins Innocrin Pharmaceuticals as CFO
May 27, 2015
Innocrin Pharmaceuticals, Inc. Initiates Phase 2 Castration-Resistant Prostate Cancer (CRPC) Study in Men Who Have Failed Enzalutmaide or Abiraterone
April 14, 2015
Innocrin Pharmaceuticals, Inc. Raises $28 Million in Series D Financing
February 26, 2015
Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study and Preclinical Results In A Clinically-Relevant Enzalutamide-Resistant Mouse Model
November 13, 2014
Innocrin Pharmaceuticals and the Prostate Cancer Foundation Join Forces for Innovative Phase 2 Clinical Study
October 22, 2014
Innocrin Pharmaceuticals Formed: Spin-Out Of Viamet Pharmaceuticals Prostate Cancer Program